These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12669466)

  • 21. Antigen presentation and DNA vaccines.
    Donnelly JJ; Liu MA; Ulmer JB
    Am J Respir Crit Care Med; 2000 Oct; 162(4 Pt 2):S190-3. PubMed ID: 11029393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Professional antigen-presentation function by human gammadelta T Cells.
    Brandes M; Willimann K; Moser B
    Science; 2005 Jul; 309(5732):264-8. PubMed ID: 15933162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approaches to improved targeting of DNA vaccines.
    Wang G; Pan L; Zhang Y
    Hum Vaccin; 2011 Dec; 7(12):1271-81. PubMed ID: 22108038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice.
    Li AF; Hough J; Henderson D; Escher A
    Vaccine; 2004 Apr; 22(13-14):1751-63. PubMed ID: 15068859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
    Pavlenko M; Leder C; Pisa P
    Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cells: open for presentation business.
    Saveanu L; van Endert P
    Nat Immunol; 2005 Jan; 6(1):7-8. PubMed ID: 15611772
    [No Abstract]   [Full Text] [Related]  

  • 27. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.
    Isaji K; Kawase A; Matono M; Guan X; Nishikawa M; Takakura Y
    J Control Release; 2009 May; 135(3):227-33. PubMed ID: 19331843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA gene fusion vaccines against cancer.
    Zhu D; Stevenson FK
    Curr Opin Mol Ther; 2002 Feb; 4(1):41-8. PubMed ID: 11883694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
    Haque A; Blum JS
    J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-presentation: underlying mechanisms and role in immune surveillance.
    Rock KL; Shen L
    Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes.
    Lu Y; Kawakami S; Yamashita F; Hashida M
    Biomaterials; 2007 Jul; 28(21):3255-62. PubMed ID: 17449093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine.
    Herd KA; Wiethe C; Tindle RW
    Vaccine; 2007 Jul; 25(28):5209-19. PubMed ID: 17544551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice.
    Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M
    Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering of DNA vaccines using molecular adjuvant plasmids.
    Sin JI; Kim J; Chattergoon M; Ayyavoo V; McCallus D; Ugen KE; Boyer JD; Weiner DB
    Dev Biol (Basel); 2000; 104():187-98. PubMed ID: 11713819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microparticles for the delivery of DNA vaccines.
    O'Hagan DT; Singh M; Ulmer JB
    Immunol Rev; 2004 Jun; 199():191-200. PubMed ID: 15233735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses.
    Kwon YJ; Standley SM; Goodwin AP; Gillies ER; Fréchet JM
    Mol Pharm; 2005; 2(1):83-91. PubMed ID: 15804181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New understanding of immunological mechanisms.
    Saalmüller A
    Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
    Calarota SA; Weiner DB
    Immunol Rev; 2004 Jun; 199():84-99. PubMed ID: 15233728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.